top of page
HemeMARK is an ultrasensitive comprehensive next-generation sequencing (NGS) blood test to detect biomarkers in hematological cancers.
Available internationally outside the USA.
HemeMARK can:
-
Inform diagnosis
-
Identify treatment targets
-
Provide prognosis
-
Monitor treatment response
-
Detect and monitor Minimal Residual Disease (MRD)
-
Profile resistance mutations
Analyzes
72
cancer-related gene mutations
20
RNA fusions
8
copy number variations (CNV)
6
microsatellite instability (MSI)
Downloads
Specifications
Single Nucleotide Variants (SNVs)
>92%
Sensitivity
>99%
Specificity
>0.05%
LOD Mutant Allele Frequency
Insertions / Deletions (indels)
>91%
Sensitivity
>99%
Specificity
>0.05%
LOD Mutant Allele Frequency
RNA fusions
>97%
Sensitivity
>99%
Specificity
10 copies
LOD Mutant Allele Frequency
bottom of page